Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis

Angela Marcobal, Mark Underwood, David A. Mills

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Label claims on probiotic products often do not represent the true constituents. With the increased use of probiotics in clinical studies, it is necessary to know the true composition of probiotic products to better interpret study outcomes. We used terminal restriction fragment length polymorphism analysis to rapidly determine the overall bacterial composition of 14 commercial probiotic products and validated the results with species-specific polymerase chain reaction. The results show that many probiotic products contain unadvertised additional lactobacilli and bifidobacteria, whereas others are missing species listed on the product label. In summary, terminal restriction fragment length polymorphism is a rapid method for profiling the microbial contents of probiotic products used in clinical studies.

Original languageEnglish (US)
Pages (from-to)608-611
Number of pages4
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume46
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Probiotics
Restriction Fragment Length Polymorphisms
probiotics
restriction fragment length polymorphism
clinical trials
product labeling
Bifidobacterium
Lactobacillus
rapid methods
polymerase chain reaction
Outcome Assessment (Health Care)
Polymerase Chain Reaction

Keywords

  • Bifidobacteria
  • Lactobacilli
  • Probiotics
  • Terminal restriction fragment length polymorphism

ASJC Scopus subject areas

  • Gastroenterology
  • Pediatrics, Perinatology, and Child Health
  • Histology
  • Medicine (miscellaneous)
  • Food Science

Cite this

@article{ad726b4c58ff4b29b6f340f7c82dc6b9,
title = "Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis",
abstract = "Label claims on probiotic products often do not represent the true constituents. With the increased use of probiotics in clinical studies, it is necessary to know the true composition of probiotic products to better interpret study outcomes. We used terminal restriction fragment length polymorphism analysis to rapidly determine the overall bacterial composition of 14 commercial probiotic products and validated the results with species-specific polymerase chain reaction. The results show that many probiotic products contain unadvertised additional lactobacilli and bifidobacteria, whereas others are missing species listed on the product label. In summary, terminal restriction fragment length polymorphism is a rapid method for profiling the microbial contents of probiotic products used in clinical studies.",
keywords = "Bifidobacteria, Lactobacilli, Probiotics, Terminal restriction fragment length polymorphism",
author = "Angela Marcobal and Mark Underwood and Mills, {David A.}",
year = "2008",
month = "5",
doi = "10.1097/MPG.0b013e3181660694",
language = "English (US)",
volume = "46",
pages = "608--611",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis

AU - Marcobal, Angela

AU - Underwood, Mark

AU - Mills, David A.

PY - 2008/5

Y1 - 2008/5

N2 - Label claims on probiotic products often do not represent the true constituents. With the increased use of probiotics in clinical studies, it is necessary to know the true composition of probiotic products to better interpret study outcomes. We used terminal restriction fragment length polymorphism analysis to rapidly determine the overall bacterial composition of 14 commercial probiotic products and validated the results with species-specific polymerase chain reaction. The results show that many probiotic products contain unadvertised additional lactobacilli and bifidobacteria, whereas others are missing species listed on the product label. In summary, terminal restriction fragment length polymorphism is a rapid method for profiling the microbial contents of probiotic products used in clinical studies.

AB - Label claims on probiotic products often do not represent the true constituents. With the increased use of probiotics in clinical studies, it is necessary to know the true composition of probiotic products to better interpret study outcomes. We used terminal restriction fragment length polymorphism analysis to rapidly determine the overall bacterial composition of 14 commercial probiotic products and validated the results with species-specific polymerase chain reaction. The results show that many probiotic products contain unadvertised additional lactobacilli and bifidobacteria, whereas others are missing species listed on the product label. In summary, terminal restriction fragment length polymorphism is a rapid method for profiling the microbial contents of probiotic products used in clinical studies.

KW - Bifidobacteria

KW - Lactobacilli

KW - Probiotics

KW - Terminal restriction fragment length polymorphism

UR - http://www.scopus.com/inward/record.url?scp=48249085783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249085783&partnerID=8YFLogxK

U2 - 10.1097/MPG.0b013e3181660694

DO - 10.1097/MPG.0b013e3181660694

M3 - Article

C2 - 18493222

AN - SCOPUS:48249085783

VL - 46

SP - 608

EP - 611

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 5

ER -